Chenodeoxycholic acid-d5 [52840-12-7]

Cat# HY-76847S3-5mg

Size : 5mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Contatta il distributore locale :


Telefono : +1 850 650 7790

Chenodeoxycholic acid-d5 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Chenodeoxycholic acid-d<sub>5</sub> Chemical Structure

Chenodeoxycholic acid-d5 Chemical Structure

CAS No. : 52840-12-7

This product is a controlled substance and not for sale in your territory.

Based on 1 publication(s) in Google Scholar

Other Forms of Chenodeoxycholic acid-d5:

  • Chenodeoxycholic Acid In-stock
Description

Chenodeoxycholic acid-d5 is the deuterium labeled Chenodeoxycholic Acid. Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

397.60

Formule

C24H35D5O4

CAS No.

52840-12-7

Unlabeled CAS

474-25-9

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@](CC[C@]2(02)[C@H](C)CCC(O)=O)(02)[C@@]3(02)[C@@](CC1)(02)[C@@]4([C@](C([2H])([2H])[C@](C([2H])([2H])C4)([2H])O)(02)C[C@H]3O)C

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité
In Vitro: 

DMSO : 50 mg/mL (125.75 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5151 mL 12.5755 mL 25.1509 mL
5 mM 0.5030 mL 2.5151 mL 5.0302 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Pureté et documentation

Purity: ≥98.0%

Références
  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

    [2]. Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002 Jul 19;277(29):26286-92  [Content Brief]

    [3]. Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012 Jul 15;11(14):2699-710  [Content Brief]

    [4]. Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. Biochem Biophys Res Commun. 1995 Mar 8;208(1):405-11.  [Content Brief]

    [5]. Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol. 2013 Aug 15;305(4):C447-56  [Content Brief]

    [6]. Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab  [Content Brief]

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Stauffer AT, et al. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002 Jul 19;277(29):26286-92

    [3]. Casaburi I, et al. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle. 2012 Jul 15;11(14):2699-710

    [4]. Kawabe Y, et al. The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells. Biochem Biophys Res Commun. 1995 Mar 8;208(1):405-11.

    [5]. Ao M, et al. Chenodeoxycholic acid stimulates Cl(-) secretion via cAMP signaling and increases cystic fibrosis transmembrane conductance regulator phosphorylation in T84 cells. Am J Physiol Cell Physiol. 2013 Aug 15;305(4):C447-56

    [6]. Noh K, et al. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β. Drug Metab

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.5151 mL 12.5755 mL 25.1509 mL 62.8773 mL
5 mM 0.5030 mL 2.5151 mL 5.0302 mL 12.5755 mL
10 mM 0.2515 mL 1.2575 mL 2.5151 mL 6.2877 mL
15 mM 0.1677 mL 0.8384 mL 1.6767 mL 4.1918 mL
20 mM 0.1258 mL 0.6288 mL 1.2575 mL 3.1439 mL
25 mM 0.1006 mL 0.5030 mL 1.0060 mL 2.5151 mL
30 mM 0.0838 mL 0.4192 mL 0.8384 mL 2.0959 mL
40 mM 0.0629 mL 0.3144 mL 0.6288 mL 1.5719 mL
50 mM 0.0503 mL 0.2515 mL 0.5030 mL 1.2575 mL
60 mM 0.0419 mL 0.2096 mL 0.4192 mL 1.0480 mL
80 mM 0.0314 mL 0.1572 mL 0.3144 mL 0.7860 mL
100 mM 0.0252 mL 0.1258 mL 0.2515 mL 0.6288 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Chenodeoxycholic acid-d5 Related Classifications

  • Metabolic Disease Cancer
  • Cancer Metabolism and Metastasis
  • Others Metabolic Enzyme/Protease Autophagy
  • Isotope-Labeled Compounds FXR Endogenous Metabolite Autophagy
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chenodeoxycholic acid-d552840-12-7CDCA-d5Isotope-Labeled CompoundsFXREndogenous MetaboliteAutophagyNR1H4Inhibitorinhibitorinhibit